We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Improved Marketing Strategies Contribute to IVD Companies' Success

By LabMedica International staff writers
Posted on 28 Jul 2009
The global economic crisis may give the in vitro diagnostics (IVD) industry an opportunity to achieve commercial success. More...
To do so the industry must earn the approval of several different groups: regulators, payer organizations, healthcare providers, and physicians, all of whom ultimately determine the value of a product and how well it will do in the market. For this reason, strategic market-focused product development and effective commercialization are crucial.

Early adopters--laboratories, leading researchers, and physicians also play an influential role in the development and commercialization of new IVD tests. They are critical to the rapid adoption of new products by most potential users, and should be part of the strategy, according to new market research.

There are several hundred new tests and test platforms in development and near market. If all of these devices make it to market, only some will successfully penetrate it. With the average cost of developing a new diagnostic test at least US$100-200 million, companies will need to improve the efficiency of their research and development and commercialization processes.

Marketing mature products involves a keen understanding of the market parameters that companies can control--product design, pricing, distribution options, and sales training and promotions. The countries where companies intend to market their products must also be considered seriously, whether it is North or South America, the United Kingdom, Europe, Japan, China, or Australia. Companies should invest in research that allows them to understand market parameters that are not in their purview to manage. These uncontrollable elements include economic trends that may result in unexpected obstacles and actions taken by competitors.

Kalorama Information's (Rockville, MD, USA) diagnostic expert, Shara Rosen, R.T. M.B.A. reported that evidence-based medicine is becoming more critical for product success as advances in medical technology create increasingly sophisticated and costly new tests. "Companies might be tempted to reduce spending on marketing in a recession,” said Ms. Rosen "But the reality is that to impress increasingly skeptical payers, they may have to spend more.”

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Kalorama Information


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.